The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

Major US oncology investment in northeast US highlights rising demand for complex treatment and cross-border care ...

The prestigious Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts, acknowledged this week that it would seek retractions for 6 papers and corrections for an additional 31 — some co-authored ...

Dana-Farber Cancer Institute says the research giant is seeking to retract six studies and correct 31 others, as local scientists face “data forgery” allegations for their cancer research. This ...

The Dana-Farber Cancer Institute, an affiliate of Harvard Medical School, is seeking to retract six scientific studies and correct 31 others that were published by the institute’s top researchers, ...

All nine patients treated at Dana-Farber Cancer Institute in a phase 1 trial of a personalized cancer vaccine for patients with stage III or IV kidney cancer with a high risk of recurrence, generated ...

The journal Science retracted a 2006 paper by Dana-Farber Cancer Institute President and CEO Laurie H. Glimcher ’72 on Thursday due to discrepancies in several figures, following data manipulation ...